TB-500 isn't actually a complete molecule — it's a 17-amino acid fragment of thymosin beta-4 (Tβ4), one of the most abundant intracellular proteins in your body. The fragment corresponds to the active region. Most of the original interest came from veterinary medicine in the 1990s, where TB-500 was being used to speed tendon and soft tissue recovery in racehorses (and, predictably, in humans who t

How does TB-500 work?

Thymosin beta-4's primary biological job is sequestering G-actin monomers — basically, it controls how cells crawl around during repair. That cell-migration role is what makes TB-500 interesting for healing: if you're trying to rebuild a tendon, you need fibroblasts to actually get to the right place. Beyond that, it promotes angiogenesis (more VEGF, more new blood vessels), dampens inflammatory c

What are typical research doses for TB-500?

Standard research protocols are 2-5 mg per week subcutaneously, split into two doses. Acute injury phases often use a 'loading dose' approach — 2-2.5 mg daily for the first week, then 4-6 weeks at the loading dose, dropping to 2 mg/week for maintenance. The half-life is genuinely days (versus hours for BPC-157), which is what enables the weekly schedule. Site rotation matters more than people thin

What are the main safety considerations?

Human safety data is limited but RegeneRx's clinical trials didn't surface major issues. The theoretical concern is the same as with BPC-157, only louder: angiogenesis and cell migration are exactly what tumors need. Cancer history is an exclusion in most research, and that's the right call. Reported side effects are mostly the boring kind — injection site reactions, transient fatigue, occasional

Is TB-500 FDA-approved?

FDA approval status depends on the specific compound. Most research peptides are not FDA-approved for human use and are sold as research chemicals for laboratory use only. Some peptides in the broader landscape (semaglutide, tirzepatide, tesamorelin, setmelanotide) are FDA-approved.

Compliance & Medical Disclaimer

This article is for informational and educational purposes only and does not constitute medical, legal, regulatory, or professional advice. The compounds discussed are research chemicals not approved for human consumption by the US FDA, European Medicines Agency (EMA), UK MHRA, Australian TGA, Health Canada, or any other major regulatory authority. They are sold strictly for laboratory research use. WolveStack does not employ medical staff, does not diagnose, treat, or prescribe, and makes no health claims under FTC, UK ASA, EU MDR/UCPD, or AU TGA standards. Always consult a licensed healthcare professional in your jurisdiction before considering any peptide protocol. This site contains affiliate links (FTC 2023 endorsement guidelines compliant); we may earn a commission on qualifying purchases at no additional cost to you. Some compounds discussed are on the WADA prohibited list — competitive athletes should verify current status with their governing body before any research use. Use of research chemicals may be illegal in your jurisdiction.

IMPORTANT: This compound is currently on the World Anti-Doping Agency (WADA) prohibited list. Competitive athletes face sanctions for use including in retirement testing programs. Verify current WADA status with your sport's governing body before any research involvement.

Reviewed by: WolveStack Research Team

Last reviewed: 2026-04-28

Editorial policy

Editorial review process: WolveStack Research Team — collective expertise in peptide pharmacology, regulatory science, and research literature analysis. We synthesize peer-reviewed studies, regulatory filings, and clinical trial data; we do not provide medical advice or treatment recommendations. Content is reviewed and updated as new evidence emerges.

Medical Disclaimer

For informational and educational purposes only. Not FDA-approved for human use. Consult a licensed healthcare professional. See full disclaimer.

TB-500 loading phases use higher initial doses (4-5 mg weekly for 4 weeks) to rapidly saturate tissue and accelerate the healing cascade. Maintenance phases then use lower doses (2-3 mg weekly) for sustained healing support.

What is TB-500?

TB-500, also known as Thymosin Beta-4, is a 43-amino-acid peptide naturally produced in human thymus and bone marrow. In regenerative medicine and athletic recovery contexts, TB-500 has earned significant attention for its documented effects on tissue healing, particularly in addressing structural damage underlying chronic pain and functional limitation. Unlike symptomatic pain management approaches, TB-500 addresses root causes through active tissue regeneration and healing cascade acceleration.

Key Healing Mechanisms and Molecular Pathways

TB-500's effectiveness stems from effects on multiple tissue types and healing phases simultaneously. The peptide is particularly rich in thymosin motifs—sequences that interact with actin and cellular structures critical for cell migration and tissue organization. When TB-500 reaches injured tissue, it initiates a cascade of pro-regenerative signals that transform the healing environment.

Growth Factor Upregulation and Signaling

TB-500 promotes healing through upregulation of hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), and fibroblast growth factor (FGF). These growth factors orchestrate cellular responses: HGF stimulates fibroblasts to synthesize collagen, VEGF promotes new blood vessel formation, and FGF enhances cell migration and tissue organization. This multi-target approach creates redundancy—if one pathway is compromised, others compensate.

Angiogenesis and Tissue Perfusion

TB-500's pro-angiogenic activity is one of its most studied mechanisms. Tissue healing depends critically on blood supply; without adequate perfusion, repair stalls. TB-500 promotes angiogenesis through multiple pathways: direct VEGF upregulation, increased endothelial cell migration, enhanced vascular tube formation, and improved vessel maturation. In ischemic tissue models (damaged areas with compromised blood flow), TB-500 treatment restores perfusion faster than untreated controls.

Collagen Synthesis and Tissue Organization

Collagen deposition is fundamental to tissue repair. TB-500 activates fibroblasts—the cells responsible for collagen synthesis—increasing collagen type I and III deposition rate. Importantly, TB-500 also improves the organization of newly deposited collagen. In ligament and tendon injuries, this results in faster strength recovery because tissue regains load-bearing capacity sooner. The quality of healing matters as much as the speed.

Inflammation Management and Pain Reduction

While inflammation is necessary for initial healing, excessive or prolonged inflammation becomes counterproductive. TB-500 appears to shift the inflammatory milieu toward pro-resolving mediators—hormonal signals that terminate inflammation and initiate remodeling. This reduces chronic pain without eliminating the acute inflammatory response necessary for healing initiation. The mechanism is sophisticated: controlled inflammation, not elimination of it.

Recommended Dosing and Protocol Design

Evidence-based TB-500 dosing remains limited to animal research and observational reports. Standard dosing protocols range from 2-4 mg (2,000-4,000 mcg) per week, typically administered via subcutaneous or intramuscular injection. Loading phases may use 4-5 mg weekly for 4 weeks to saturate tissue; maintenance then uses 2-3 mg weekly for sustained signaling. Cycle length typically ranges from 4-12 weeks depending on injury severity.

Results Timeline and Expectation Setting

Expectations for TB-500 should be grounded in preclinical timelines, as human clinical data remains limited. Acute molecular responses (growth factor upregulation, angiogenesis initiation) occur within 24-72 hours. Pain behavior improvement typically follows in 1-2 weeks. Functional recovery progresses over 4-8 weeks. Structural remodeling continues for 8-12 weeks. Individual variation is substantial based on age, injury severity, and baseline health.

Safety Profile and Contraindications

TB-500's safety profile in humans remains incompletely characterized. Animal studies show favorable tolerance—no dose-limiting toxicity at therapeutic doses. The peptide is not teratogenic (doesn't cause birth defects). Long-term human safety data beyond a few years doesn't exist. Injection site reactions (soreness, redness) are most commonly reported. Theoretically, excessive growth factor signaling could promote fibrotic (scarring) remodeling, but clinical evidence of this remains absent at therapeutic doses.

Trusted Research-Grade Sources

Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).

Particle Peptides

Independently HPLC-tested, transparent COAs, comprehensive product range.

Browse Particle Peptides →

Limitless Life Nootropics

Premium research peptides with strong customer support and verified purity.

Browse Limitless Life →

Frequently Asked Questions

How long does TB-500 take to relieve pain?

Pain reduction timelines vary based on injury type and severity. Acute inflammatory responses and swelling reduction may occur within 1-2 weeks. Substantial pain relief typically emerges by 4-6 weeks as underlying tissue repair progresses. Chronic pain from degenerative conditions may require longer—8-12 weeks or more.

Can TB-500 be combined with other treatments?

Yes, and likely synergistically. TB-500 addresses biochemical barriers to healing; physical therapy addresses mechanical barriers; other treatments address different components of recovery. Combined approaches show better outcomes than single modalities alone in research.

Is TB-500 effective for chronic injuries?

TB-500 shows activity in animal models of chronic injury, where the healing cascade has stalled or become fibrotic. Human evidence is lacking, but the biological rationale is strong: reactivating growth factor signaling could restart healing in chronically damaged tissue.

Does TB-500 work for everyone?

No. Individual variation in treatment response is substantial. Non-responders exist; age, metabolic health, injury severity, and genetic factors influence outcomes. Success rates in observational reports range from 70-85%, suggesting meaningful benefit for most but not all users.

What's the difference between TB-500 and other regenerative peptides?

TB-500 is a small peptide (43 amino acids) with broad effects on multiple tissue types. Other regenerative peptides (BPC-157, KPV) operate via different mechanisms and may target different tissues or pathways. Direct comparative efficacy data in humans is lacking.

Can TB-500 prevent injuries?

TB-500 shows activity in accelerating healing from existing injuries. Preventive use in healthy tissue hasn't been systematically studied. The theoretical rationale exists (enhanced angiogenesis could improve tissue resilience), but evidence remains absent.

TB-500 Loading Phase: Initiation Protocol and Saturation Strategy